### Check for updates

### **OPEN ACCESS**

EDITED AND REVIEWED BY Luis Abel Quiñones. University of Chile, Chile

\*CORRESPONDENCE Laurence McEvoy, □ l.mcevoy@liverpool.ac.uk Munir Pirmohamed, munirp@liverpool.ac.uk

RECEIVED 07 August 2023 ACCEPTED 15 August 2023 PUBLISHED 31 August 2023

#### CITATION

McEvoy L, Cliff J, Carr DF, Jorgensen A, Lord R and Pirmohamed M (2023), Corrigendum: CYP3A genetic variation and taxane-induced peripheral neuropathy: a systematic review, metaanalysis, and candidate gene study. Front. Pharmacol. 14:1274075 doi: 10.3389/fphar.2023.1274075

### COPYRIGHT

© 2023 McEvoy, Cliff, Carr, Jorgensen, Lord and Pirmohamed. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Corrigendum: CYP3A genetic variation and taxane-induced peripheral neuropathy: a systematic review, meta-analysis, and candidate gene study

### Laurence McEvoy<sup>1</sup>\*, Joanne Cliff<sup>2</sup>, Daniel F Carr<sup>1</sup>, Andrea Jorgensen<sup>3</sup>, Rosemary Lord<sup>2</sup> and Munir Pirmohamed<sup>1\*</sup>

<sup>1</sup>Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, United Kingdom, <sup>2</sup>Clatterbridge Cancer Centre, Liverpool, United Kingdom, <sup>3</sup>Health Data Science, University of Liverpool, Liverpool, United Kinadom

### **KEYWORDS**

chemotherapy, cytochrome P450, peripheral neuropathy, personalised medicine, pharmacogenetics

### A Corrigendum on

CYP3A genetic variation and taxane-induced peripheral neuropathy: a systematic review, meta-analysis, and candidate gene study

by McEvoy L, Cliff J, Carr DF, Jorgensen A, Lord R and Pirmohamed M (2023). Front. Pharmacol. 14:1178421. doi: 10.3389/fphar.2023.1178421

In the published article, there was an error in the legend and artwork for Figure 2 as published. Additional information relating to variant carriage or non-carriage needed. Forest Plot data was incorrectly reported. The corrected Figure 2 and its caption appears below.

In the published article, there was an error. Meta-analysis data from Figure 2 was incorrectly reported in the Results.

A correction has been made to 3 Results, 3.4 Meta-analysis, paragraphs 2 and 3. These sentences previously stated:

"For CYP3A4\*22, sufficient data was available from 2 studies (de Graan et al., 2013; Di Francia et al., 2017). Combining this with the data we generated showed that there was no association between CYP3A4\*22 and PN (OR 1.1; 95% CI 0.62-1.97; I<sup>2</sup> 42%; p = 0.74).

For CYP3A5\*3, sufficient data was available from 2 studies (Eckhoff et al., 2015a; Hu et al., 2016). Combining these two studies with the data from our candidate gene analysis again showed no association between CYP3A5\*3 and PN (OR 0.99; 95% CI 0.57-1.71;  $I^2 = 0\%$ ; p = 0.97)." The corrected sentences appear below:

"For CYP3A4\*22, sufficient data was available from 2 studies (de Graan et al., 2013; Di Francia et al., 2017). Combining this with the data we generated showed that there was no association between *CYP3A4\*22* and PN (OR 1.22; 95% CI 0.69–2.16;  $l^2$  55%; p = 0.49).

For CYP3A5\*3, sufficient data was available from 2 studies (Eckhoff et al., 2015a; Hu et al., 2016). Combining these two studies with the data from our candidate gene analysis again showed no association between CYP3A5\*3 and PN (OR 1.15; 95% CI 0.67–1.98;  $I^2 = 0\%$ ; p = 0.61)."

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

	Peripheral net	uropathy	Tolerant	Control		Odds Ratio		Odds Ratio	
Study or Subgroup	Events	Tota	I Events	Tota	l Weight	M-H, Fixed, 95% CI		M-H, Fixed, 95% Cl	
de Graan AJ et al 2013	10	44	51	44	7 34.1%	2.28 [1.06, 4.90]			
Di Francia R et al 2017	3	23		1:	2 11.0%	0.75 [0.11, 5.24]			
McEvoy L et al 2023	6	54	25	15	7 54.9%	0.66 [0.26, 1.71]			
Total (95% CI)		121	(	61	6 100.0%	1.22 [0.69, 2.16]		+	
Total events	19		78						
Heterogeneity: Chi <sup>2</sup> = 4 Test for overall effect: Z		1); I² = 559	Хо				0.01	0.1 1 10 Favours Control Favours Case	10
Study or Subgroup	Peripheral neuro		olerant Co		Noight M	Odds Ratio		Odds Ratio	
Study or Subgroup	Events	Total	Events	Total \		I-H, Random, 95% CI		Odds Ratio M-H, Random, 95% Cl	
Eckhoff L et al 2015	Events 65	Total 75	Events 61	Total 1 75	38.1%	I-H, Random, 95% Cl 1.49 [0.62, 3.61]			
, , ,	Events	Total	Events	Total 1 75 45		I-H, Random, 95% CI			
Eckhoff L et al 2015 Hu L et al 2015	Events 65 15	Total 75 30	Events 61 25	Total 1 75 45 157	38.1% 34.6%	I-H, Random, 95% CI 1.49 [0.62, 3.61] 0.80 [0.32, 2.02]			
Eckhoff Let al 2015 Hu Let al 2015 McEvoy Let al 2023	Events 65 15	Total 75 30 54	Events 61 25	Total 1 75 45 157	38.1% 34.6% 27.3%	I-H, Random, 95% CI 1.49 [0.62, 3.61] 0.80 [0.32, 2.02] 1.27 [0.45, 3.60]			

Association between *CYP3A4\*22* and *CYP3A5\*3* variants and taxane-induced peripheral neuropathy. (A). Association between *CYP3A4\*22* and taxane-induced peripheral neuropathy. Analysis of \*22 carriage (\*1/\*22 and \*22/\*22) vs. non-carriage (\*1/\*1). Note: The phenotype definition for cases in Di Francia *et al.* (2017) differed from our phenotype definition of Grade 2 PN and above. Di Francia *et al.* (2017) considered Grade 1 and above as cases. (B). Association between *CYP3A5\*3* and taxane-induced peripheral neuropathy. Analysis of \*3 homozygous carriage (\*3/\*3) vs. non-carriage and heterozygous carriage (\*1/\*1 and \*1/\*3).

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.